Biogen Inc

BIIB · Moat type: REGULIERUNG

MoatScore

5/10

Fair Value

266 USD

Margin of Safety

+18.7 %

Rating

BEOBACHTEN

Biogen develops, manufactures, and markets biologics and therapies for neurological and neurodegenerative diseases such as multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease, and generates revenue primarily through drug sales as well as licensing and cooperation agreements.

View full analysis →

🔒 Detailed AI analysis, peer comparison, capital allocation, crisis resilience & PDF report for Pro members.

Not investment advice. Analyses are research, not a recommendation. Valuations may be erroneous or incomplete. © MoatScan.ai — proprietary methodology.